Poor
Not Aligned
Patient Risk:
Medium
Summary
The response includes numerous indication and formulation claims that are not supported by the provided label text/sections. Only general pharmacology statements (antihistamine; histamine receptor competition; anticholinergic/sedative) are supported. Multiple symptom-based uses (common cold/allergy manifestations like sneezing, runny nose, itchy/watery eyes, hives, insect bites) are not supported by the provided label content, and the motion sickness claim is only partially supported. Safety/administration details are not provided in the response, preventing verification of label-aligned contraindications/warnings/dosing/population restrictions.
Category Scores
Accurate Statements
Diphenhydramine is an antihistamine.
Supported by provided label text under CLINICAL PHARMACOLOGY ('Diphenhydramine hydrochloride is an antihistamine ...').
Diphenhydramine blocks the action of histamine.
Supported by provided label text under CLINICAL PHARMACOLOGY ('appear to compete with histamine for cell receptor sites ...').
Diphenhydramine has anticholinergic properties that contribute to its sedating effects.
Supported by provided label text under CLINICAL PHARMACOLOGY ('anticholinergic (drying) and sedative side effects.').
Unsupported Statements
Diphenhydramine is used to treat symptoms of the common cold.
Not supported by the provided label excerpts (INDICATIONS/USAGE excerpt references injectable use when oral is impractical; no common cold indication provided).
Diphenhydramine is used to treat allergy symptoms such as sneezing.
Not supported by the provided label excerpts.
Diphenhydramine is used to treat allergy symptoms such as runny nose.
Not supported by the provided label excerpts.
Diphenhydramine is used to treat allergy symptoms such as itchy throat.
Not supported by the provided label excerpts.
Diphenhydramine is used to treat allergy symptoms such as itchy or watery eyes.
Not supported by the provided label excerpts.
Diphenhydramine relieves itching from hives.
Not supported by the provided label excerpts.
Diphenhydramine relieves itching from insect bites.
Not supported by the provided label excerpts.
Diphenhydramine can be used as a short-term sleep aid.
Not supported by the provided label excerpts.
Diphenhydramine is used to treat nausea, vomiting, and dizziness caused by motion sickness.
Only partially supported: label says 'For active treatment of motion sickness' but does not specifically mention nausea/vomiting/dizziness in the provided excerpt.
Diphenhydramine is a first-generation antihistamine.
Not supported by the provided label excerpts.
Histamine is a substance in the body that causes allergic symptoms.
Not supported by the provided label excerpts.
Diphenhydramine is available in oral tablets.
Not supported by the provided label excerpts (HOW SUPPLIED excerpt is for injectable products).
Diphenhydramine is available in oral capsules.
Not supported by the provided label excerpts.
Diphenhydramine is available in liquid solutions.
Not supported by the provided label excerpts.
Diphenhydramine is available in topical creams.
Not supported by the provided label excerpts.
Diphenhydramine is available in topical sprays.
Not supported by the provided label excerpts.
Diphenhydramine hydrochloride generic name is diphenhydramine.
Marked absent from the label by provided label-claim evaluation; generic-name equivalence is not supported by the supplied label excerpts.
Contradictions
Important Omissions
Label-aligned indication framing for the provided formulation (injectable form): effective when oral form is impractical; and other specific injectable indications for immediate-type allergic conditions/anaphylaxis adjunct, motion sickness active treatment, and antiparkinsonism when oral is impossible/contraindicated.
Importance:
High
Dosage and administration details for injectable use (IV/IM only; individualized dosing; specific adult/pediatric dosing ranges and administration rate/maximum daily dose).
Importance:
High
Key safety statements present in the provided label excerpts (caution in specific conditions; local necrosis associated with subcutaneous/intradermal use; drug interaction warnings such as additive effects with alcohol/CNS depressants and MAO inhibitor prolongation/intensification; overdosage risk patterns and treatment principles).
Importance:
High
Use in specific populations contained in provided excerpts (contraindication in neonates/premature infants; nursing mothers contraindication; pediatric overdosage risks; elderly increased risk for dizziness/sedation/hypotension; pregnancy use only if clearly needed).
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
The response assigns multiple symptom-based indications (common cold; specific allergy manifestations; hives/insect bites; sleep aid) that are not supported by the provided label excerpts. It also omits multiple safety-critical label elements (dose/route constraints for injectable product, population restrictions, interaction warnings, and cautions). While no direct contradictions are present in the provided label excerpts, the combination of unsupported uses and major omissions could lead to misapplication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple indication and formulation claims are unsupported by the provided FDA label excerpts; motion sickness wording is only partially supported; major label safety and administration/population content is omitted.
Suggested Improvement
Restrict claims to those explicitly supported by the provided label excerpts (e.g., antihistamine; histamine receptor competition; anticholinergic/sedative effects; motion sickness active treatment for injectable when oral is impractical). Add required injectable administration/route, population restrictions (neonates/premature; nursing mothers), and the interaction/caution/overdosage warnings included in the label excerpts.